Trevi Therapeutics, Inc.(TRVI)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
TRVI Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Trevi Therapeutics, Inc. (TRVI), a Healthcare sector company. TRVI is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Trevi Therapeutics, Inc. reports net income of $-13.2M, free cash flow of $-16.8M. Top institutional holders of TRVI by reported 13-F value include NEA Management Company,, BlackRock,, Frazier Life Sciences Management, L.P., based on the most recent SEC filings. TRVI trades on the Nasdaq exchange and files with the SEC under CIK 1563880. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TRVI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Trevi Therapeutics, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-13.2M
Free Cash Flow
Q1 2026
$-16.8M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
+10.8% YoYOperating Income
+4.3% YoYEPS (Diluted)
+31.9% YoYTotal Assets
+74.4% YoYOp. Cash Flow
-10.0% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-42.8M +10.8% | $-47.9M -64.8% | $-29.1M +0.3% | $-29.2M +14.1% | $-33.9M -3.6% | $-32.8M |
| Operating Income | $-49.3M +4.3% | $-51.5M -51.9% | $-33.9M -13.4% | $-29.9M +7.9% | $-32.5M +0.0% | $-32.5M |
| EPS (Diluted) | $-0.32 +31.9% | $-0.47 -62.1% | $-0.29 +35.6% | $-0.45 +69.8% | $-1.49 | — |
| Total Assets | $193.4M +74.4% | $110.9M +24.0% | $89.4M -27.3% | $123.0M +219.7% | $38.5M -18.4% | $47.1M |
| Operating Cash Flow | $-42.1M -10.0% | $-38.3M -20.6% | $-31.7M -12.5% | $-28.2M +2.7% | $-28.9M +0.2% | $-29.0M |
AI Insight: TRVI Financial Trends
Trevi remains pre-revenue with losses holding steady, but a sharp Q1 2026 cash burn spike and steadily eroding equity demand close monitoring.
• No revenue recorded across all eight quarters; company is entirely pre-commercial, funding operations through equity.
• Equity surged from $59M in Q3 2024 to $198M in Q2 2025, likely reflecting a capital raise, then declined to $172M by Q1 2026.
• Operating losses narrowed to $-10M in Q4 2025 before widening to $-15M in Q1 2026, the largest single-quarter loss in the dataset.
⚠ Operating cash outflow spiked to $-17M in Q1 2026 — worst in eight quarters — suggesting accelerating cash consumption.
⚠ Equity has declined $26M over three consecutive quarters from Q2 2025 peak; runway erosion will require monitoring.
⚠ Any first revenue recognition would mark a critical inflection; absence of revenue guidance keeps near-term outlook opaque.
AI Insight: TRVI Ratio Trends
Return metrics improved sharply from Q3 2024's trough but Q1 2026 shows a renewed step-down, signaling ongoing cash burn with no profitability in sight.
• ROE improved from -89.8% in Q3 2024 to -18.1% in Q4 2025, a substantial multi-quarter recovery.
• ROIC followed the same path, rebounding from -95.5% in Q3 2024 to -22.3% in Q4 2025.
• Q1 2026 ROE deteriorated to -30.7% and ROIC to -34.6%, reversing the prior improvement trend.
⚠ Q1 2026 ROIC declined ~12pp quarter-over-quarter to -34.6% — first meaningful re-deterioration after six quarters of improvement.
⚠ OpMargin, NPM, and D/E are entirely absent across all periods, limiting visibility into cost structure and leverage.
Get alerted when TRVI's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Trevi Therapeutics, Inc. including:
Top Institutional Holders of TRVI
NEA Management Company, LLC
$157.7M13,222,228 shBlackRock, Inc.
$122.2M10,240,186 shFrazier Life Sciences Management, L.P.
$118.6M9,939,547 shFMR LLC
$95.9M8,038,061 shWELLINGTON MANAGEMENT GROUP LLP
$61.9M5,189,088 shVivo Capital, LLC
$60.8M5,094,668 shVANGUARD CAPITAL MANAGEMENT LLC
$59.4M4,978,567 shMARSHALL WACE, LLP
$47.3M3,966,019 shRubric Capital Management LP
$44.3M3,712,373 shMPM BioImpact LLC
$39.4M3,298,430 sh
| Fund | Value | Shares |
|---|---|---|
| NEA Management Company, LLC | $157.7M | 13,222,228 |
| BlackRock, Inc. | $122.2M | 10,240,186 |
| Frazier Life Sciences Management, L.P. | $118.6M | 9,939,547 |
| FMR LLC | $95.9M | 8,038,061 |
| WELLINGTON MANAGEMENT GROUP LLP | $61.9M | 5,189,088 |
| Vivo Capital, LLC | $60.8M | 5,094,668 |
| VANGUARD CAPITAL MANAGEMENT LLC | $59.4M | 4,978,567 |
| MARSHALL WACE, LLP | $47.3M | 3,966,019 |
| Rubric Capital Management LP | $44.3M | 3,712,373 |
| MPM BioImpact LLC | $39.4M | 3,298,430 |
More Healthcare Companies
View all Healthcare →Put TRVI on your watchlist
Track score changes the day Trevi Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is TRVI a good stock to buy?
13F Pro's AI-powered analysis of Trevi Therapeutics, Inc. (TRVI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TRVI are available on the TRVI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own TRVI?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TRVI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Trevi Therapeutics, Inc.'s investment landscape.